Sevelamer reduces calcium load and maintains a low calcium-phosphorus ion product in dialysis patients

Journal of Nephrology

Volumn 14, Issue 3, 2001, Pages 176-183

  Gallieni, M ^a   Cozzolino, M ^a   Carpani, P ^a   Zoni, U ^a   Brancaccio, D ^a  

^a FATEBENEFRATELLI HOSPITAL   (Italy)

Author keywords

Calcium; Dialysis; Hyperphosphatemia; Phosphate; Renal osteodystrophy; Sevelamer

Indexed keywords

ALUMINUM DERIVATIVE; CALCIUM CARBONATE; CALCIUM ION; MAGNESIUM; PHOSPHATE; PHOSPHATE BINDING AGENT; SEVELAMER;

ADULT; AGED; ARTICLE; CALCIUM INTAKE; CALCIUM METABOLISM; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; COHORT ANALYSIS; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DRUG CAPSULE; DRUG EFFICACY; DRUG TOLERABILITY; DYSPEPSIA; FEMALE; HEARTBURN; HEMODIALYSIS PATIENT; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; MALE; NAUSEA; PHOSPHATE BLOOD LEVEL; PHOSPHATE METABOLISM; RENAL OSTEODYSTROPHY; SKIN DISEASE; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; CALCIUM; EPOXY COMPOUNDS; FEMALE; HUMANS; MALE; MIDDLE AGED; PHOSPHORUS; POLYAMINES; POLYETHYLENES; RENAL DIALYSIS;

EID: 0034961501     PISSN: 11218428     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Effect of phosphate on the parathyroid gland: Direct and indirect?
2. Phosphorus restriction prevents parathyroid gland growth. High phosphorus directly stimulates PTH secretion in vitro
3. Long-term control of hyperparathyroidism in advanced renal failure by low-phosphorus diet supplemented with calcium (without changes in plasma calcitriol)
4. The role of phosphorus restriction in the prevention of secondary hyperparathyroidism in chronic renal disease
5. Phosphorus restriction reverses hyperparathyroidism in uremia independent of changes in calcium and calcitriol
6. Which causes of death are related to hyperphosphatemia in hemodialysis (HD) patients?
7. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study
8. Treatment of hyperparathyroidism - Why is it crucial to control serum phosphate?
9. Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients
10. Aluminium: Much ado about something
11. Etiology of hypercalcemia in hemodialysis patients on calcium carbonate therapy
12. Are we mismanaging calcium and phosphate metabolism in renal failure?
13. A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients
14. Poly[allylamine hydrochloride] (Renagel): A non calcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure
15. A randomized trial of sevelamer hydrochloride (RenaGel) with and without supplemental calcium. Strategies for the control of hyperphosphatemia and hyperparathyroidism in hemodialysis patients
16. Simultaneous lowering of serum phosphate and LDL-cholesterol by sevelamer hydrochloride (RenaGel) in dialysis patients
17. Effect of RenaGel, a non absorbed, calcium- and aluminum-free phosphate binder, on serum phosphorus, calcium and intact parathyroid hormone in end-stage renal disease patients
18. RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. The RenaGel Study Group
19. Long-term effects of sevelamer hydrochloride on the calcium × phosphate product and lipid profile of haemodialysis patients
20. The validity of a telephone administered 24-hour recall methodology
21. Hyperphosphatemia: Its consequences and treatment in patients with chronic renal disease
22. Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: Recommendations for a change in management
23. Calciphylaxis in patients on hemodialysis: A prevalence study
24. Visceral calcification and the Ca × P product
25. Soft tissue calcification in chronic renal failure
26. Control of hyperphosphatemia in renal failure: Role of aluminum
27. Phosphate binders and mineral status of adult renal disease patients on hemodialysis
28. Effect of the time of administration of calcium acetate on phosphorus binding
29. Sevelamer with and without calcium and vitamin D: Observations from a long-term open-label clinical trial
30. Oral phosphate binders without aluminium and calcium - a pipe-dream?
31. Phosphate binders on iron basis: A new perspective?
32. New phosphate binding agents: Ferric compounds
33. Cross-linked iron dextran is an efficient oral phosphate binder in the rat
34. Stabilized polynuclear iron hydroxide is an efficient oral phosphate binder in uraemic patients
35. Phosphate-binding capacity of ferrihydrite versus calcium acetate in rats
36. A possible non-aluminum oral phosphate binder? A comparative study on dietary phosphorus absorption
37. Effect of ferric polymaltose complex as a phosphate binder in haemodialysis patients
38. Calcific small vessel ischemic disease (calciphylaxis) in dialysis patients
39. Evidence for abnormal calcium homeostasis in patients with adynamic bone disease
40. Hyperphosphatemia - A silent killer of patients with renal failure?
41. Hospitalization risks between Renagel phosphate binder treated and non-Renagel treated patients
42. Epidemiology of cardiovascular disease in chronic renal disease
43. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis